Literature DB >> 326117

Cis-diamminedichloroplatinum (II). A new anticancer drug.

M Rozencweig, D D von Hoff, M Slavik, F M Muggia.   

Abstract

Cis-diamminedichloroplatinum (II) (DDP) leads the series of platinum coordination complexes, a new class of cytotoxic agents. The antitumor and toxic effects of this drug are discussed. It has displayed encouraging results in testicular tumors. The drug's therapeutic effectiveness has also been recognized in a variety of other solid tumors, particularly ovarian, bladder, and head and neck malignancies. Gastrointestinal, renal, audiologic, and relatively minor hematologic toxicities may be encountered, but promising methods have been developed to increase the therapeutic index of DDP.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 326117     DOI: 10.7326/0003-4819-86-6-803

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  72 in total

1.  Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study.

Authors:  L S Ashby; W R Shapiro
Journal:  J Neurooncol       Date:  2001-01       Impact factor: 4.130

2.  Antitumorigenic Evaluation of Thalidomide Alone and in Combination with Cisplatin in DBA2/J Mice.

Authors:  Jean Marie B. Ruddy; Shyamal K. Majumdar
Journal:  J Biomed Biotechnol       Date:  2002

3.  Cisplatin-induced reductions in renal functional reserve uncovered by unilateral nephrectomy: an experimental study in the pig.

Authors:  M E Robbins; D Campling; E Whitehouse; J W Hopewell; A Michalowski
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 4.  Synthetic methods for the preparation of platinum anticancer complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Chem Rev       Date:  2013-11-27       Impact factor: 60.622

5.  Attenuation of cisplatinum-induced nephrotoxicity in the rat by high salt diet, furosemide and acetazolamide.

Authors:  H T Heidemann; J F Gerkens; E K Jackson; R A Branch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-04       Impact factor: 3.000

6.  Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin.

Authors:  C L Bregman; P D Williams
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Pharmacokinetics and plasma protein binding of two platinum cytostatics CHIP and CBDCA in rats.

Authors:  A Láznícková; M Láznícek; J Kvĕtina; J Drobník
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  A pilot study of cis-diamminedichloroplatinum and radiation therapy in patients with high grade astrocytomas.

Authors:  L G Feun; D J Stewart; M Maor; M Leavens; N Savaraj; M A Burgess; W K Yung; R S Benjamin
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

9.  Phase II study of cisplatin in recurrent astrocytomas in adults: a Southwest Oncology Group Study.

Authors:  D J Stewart; R M O'Bryan; M Al-Sarraf; J J Costanzi; N Oishi
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

10.  Cisplatin plus cytosine arabinoside in adults with malignant gliomas.

Authors:  D J Stewart; M T Richard; B Benoit; H Hugenholtz; N Russell; J Dennery; E Peterson; Z Grahovac; G Belanger; S Aitkens
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.